Skip to main content
. Author manuscript; available in PMC: 2023 Dec 16.
Published in final edited form as: Immunopharmacol Immunotoxicol. 2019 Jun 2;41(3):361–369. doi: 10.1080/08923973.2019.1616754

Figure 4. Inhibition of fatty acid synthesis by TOFA suppresses pDC and cDC upregulation of CD86.

Figure 4.

Purified pDCs (A) and cDCs (B) were treated for 1h with TOFA (doses expressed in μM), an inhibitor of acetyl-CoA carboxylase-α, then stimulated with TLR9 agonist CpGA 5μg/ml. Activation was measured after 24h by CD86 expression via flow cytometry. pDCs were gated for B220+CD11c+CD11b-. cDCs were gated for B220-CD11c+CD11b+. Viability of cells (C) is expressed as % of cells negative for the Fixable Viability Dye. Results are shown as the mean ± SEM, from 5 independent experiments. Significance was calculated by one-way ANOVA and multiple comparisons post-hoc correction test, and P-values marked in the figures as * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001 were considered significant.